DPP-4 inhibitor

Sitagliptin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

SITAGLIPTIN

Agent: sitagliptin
Dosing: fixed
Mechanism: Dipeptidyl peptidase 4 inhibitor
Trials: 22
Participants in these arms: 4,767

Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.47 (-0.70 to -0.22)	0.18
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.59 (-0.93 to -0.23)	0.29
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.59 (-0.81 to -0.37)	0.23
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.60 (-0.81 to -0.35)	0.28
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD 0.79 (0.37 to 1.24)	0.04
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD 0.21 (-0.64 to 1.15)	0.22
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD -0.85 (-1.74 to 0.59)	0.34
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD -0.55 (-1.05 to 0.11)	0.41
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD -0.82 (-1.42 to -0.01)	0.56
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.76 (-1.36 to 0.55)	0.20
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.43 (-1.26 to 0.82)	0.23
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.36 (-0.73 to 0.03)	0.18
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.57 (-1.21 to 0.17)	0.29
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -0.23 (-1.00 to 0.51)	0.20
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -0.68 (-1.82 to 0.42)	0.31
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD 0.72 (-1.28 to 3.25)	0.23
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -0.06 (-3.88 to 4.49)	0.41
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD 0.13 (-0.65 to 0.88)	0.39
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD 0.27 (-0.64 to 1.21)	0.47
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -0.63 (-2.48 to 1.60)	0.20
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -1.46 (-4.22 to 2.08)	0.34
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -1.58 (-6.25 to 4.06)	0.41
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -3.80 (-10.17 to 5.35)	0.74
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -4.34 (-10.48 to 3.57)	0.75
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -0.84 (-1.82 to 0.27)	0.20
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 20 to 36 (target week 26)	Placebo	MD -0.95 (-4.34 to 3.01)	0.30
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 20 to 36 (target week 26)	Placebo	OR 1.81 (0.41 to 5.09)	0.15
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 20 to 36 (target week 26)	Placebo	OR 3.70 (0.86 to 9.76)	0.26
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 36 to 64 (target week 52)	Placebo	OR 2.12 (0.35 to 7.39)	0.26
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 36 to 64 (target week 52)	Placebo	OR 2.49 (0.66 to 5.74)	0.33
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 36 to 64 (target week 52)	Placebo	OR 2.87 (0.44 to 9.40)	0.33
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 20 to 36 (target week 26)	Placebo	OR 2.19 (0.79 to 5.42)	0.25
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 20 to 36 (target week 26)	Placebo	OR 2.69 (0.97 to 6.27)	0.28
Type 2 diabetes (adults)	HbA1c below 7 percent	weeks 20 to 36 (target week 26)	Placebo	OR 4.37 (0.70 to 13.31)	0.32
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.15 (0.03 to 0.62)	0.68
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.12 (0.02 to 0.51)	0.69
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.10 (0.01 to 0.58)	0.94
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.11 (0.01 to 0.66)	0.96
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.94 (0.51 to 1.62)	0.67
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 1.03 (0.55 to 1.82)	0.70
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.93 (0.46 to 1.83)	0.51
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.82 (0.36 to 1.77)	0.58
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -2.07 (-3.41 to -0.60)	0.47
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -1.52 (-3.03 to 0.11)	0.46
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD 5.28 (0.09 to 10.47)	0.23
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD 0.79 (-2.68 to 5.05)	0.44
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD -0.79 (-7.48 to 6.67)	0.20
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD 0.07 (-9.24 to 11.78)	0.23
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD 0.49 (-2.62 to 3.77)	0.39
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -0.69 (-5.84 to 4.13)	0.57
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Semaglutide 3 mg oral once daily (original tablet)	MD -0.99 (-12.18 to 11.01)	0.65
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -2.88 (-18.10 to 13.03)	0.69
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -1.74 (-5.49 to 2.00)	0.34
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -2.69 (-6.59 to 1.32)	0.39
Type 2 diabetes (adults)	Percent body weight change	weeks 40 to 104 (target week 68)	Semaglutide tablet	MD 2.45 (-4.49 to 8.86)	0.25
Type 2 diabetes (adults)	Percent body weight change	weeks 40 to 104 (target week 68)	Placebo	MD -1.21 (-3.94 to 2.32)	0.29
Type 2 diabetes (adults)	Percent body weight change	weeks 40 to 104 (target week 68)	Placebo	MD -2.05 (-6.35 to 2.74)	0.52
Type 2 diabetes (adults)	Percent body weight change	weeks 20 to 40 (target week 26)	Placebo	MD -1.13 (-3.26 to 1.35)	0.25
Type 2 diabetes (adults)	Percent body weight change	weeks 20 to 40 (target week 26)	Placebo	MD -2.75 (-7.93 to 2.71)	0.54
Type 2 diabetes (adults)	Percent body weight change	weeks 20 to 40 (target week 26)	Placebo	MD 0.98 (-5.14 to 7.79)	0.15
Type 2 diabetes (adults)	Percent body weight change	weeks 20 to 40 (target week 26)	Placebo	MD 0.93 (-6.24 to 8.46)	0.18
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 0.83 (0.21 to 2.57)	0.08
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 2.14 (0.39 to 7.86)	0.29
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 40 to 104 (target week 68)	Placebo	OR 1.02 (0.19 to 4.13)	0.21
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 1.20 (0.37 to 3.20)	0.21
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 2.09 (0.40 to 6.77)	0.39
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 40 to 104 (target week 68)	Placebo	OR 1.42 (0.41 to 3.48)	0.25
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 40 to 104 (target week 68)	Placebo	OR 2.01 (0.58 to 4.95)	0.48
Type 2 diabetes (adults)	Weight loss of 5 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 0.43 (0.08 to 2.05)	0.03
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 0.44 (0.05 to 2.95)	0.07
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 0.96 (0.09 to 7.86)	0.12
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 1.27 (0.25 to 5.99)	0.27
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 20 to 40 (target week 26)	Placebo	OR 1.88 (0.17 to 11.76)	0.33
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 40 to 104 (target week 68)	Placebo	OR 1.64 (0.39 to 5.74)	0.49
Type 2 diabetes (adults)	Weight loss of 10 percent or more	weeks 40 to 104 (target week 68)	Placebo	OR 2.37 (0.45 to 9.57)	0.60
Type 2 diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Placebo	MD -0.03 (-0.97 to 0.92)	0.44
Type 2 diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Placebo	MD -0.05 (-1.18 to 1.08)	0.37
Type 2 diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Placebo	MD -0.14 (-3.26 to 3.10)	0.37
Type 2 diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Semaglutide 3 mg oral once daily (original tablet)	MD 0.03 (-7.05 to 7.56)	0.49
Type 2 diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Semaglutide tablet	MD 0.04 (-7.74 to 7.94)	0.46
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 0.98 (0.81 to 1.18)	0.49
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 0.93 (0.76 to 1.14)	0.55
Type 2 diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 0.62 (0.41 to 0.91)	0.79
Type 2 diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 0.68 (0.45 to 1.00)	0.74
Type 2 diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.78 (0.60 to 1.01)	0.82
Type 2 diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.73 (0.52 to 1.00)	0.67
Type 2 diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 0.85 (0.59 to 1.20)	0.79
Type 2 diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 0.86 (0.55 to 1.30)	0.70
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.77 (0.61 to 0.98)	0.80
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.78 (0.60 to 1.01)	0.75
Type 2 diabetes (adults)	Constipation	longest follow-up	Placebo	HR 0.56 (0.33 to 0.94)	0.80
Type 2 diabetes (adults)	Constipation	longest follow-up	Placebo	HR 0.71 (0.43 to 1.19)	0.68
Type 2 diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 0.21 (0.06 to 0.64)	0.84
Type 2 diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 0.22 (0.06 to 0.63)	0.78
Type 2 diabetes (adults)	Gallbladder and biliary disease	longest follow-up	Placebo	HR 0.20 (0.00 to 4.75)	0.76
Type 2 diabetes (adults)	Gallbladder and biliary disease	longest follow-up	Placebo	HR 0.23 (0.00 to 4.99)	0.75
Type 2 diabetes (adults)	Acute pancreatitis	longest follow-up	Placebo	HR 0.21 (0.02 to 1.72)	0.76
Type 2 diabetes (adults)	Acute pancreatitis	longest follow-up	Placebo	HR 0.19 (0.02 to 1.51)	0.73
Type 2 diabetes (adults)	Diabetic retinopathy complications	longest follow-up	Placebo	HR 2.30 (0.53 to 10.31)	0.26
Type 2 diabetes (adults)	Diabetic retinopathy complications	longest follow-up	Placebo	HR 2.37 (0.54 to 9.57)	0.19
Type 2 diabetes (adults)	Pancreatic cancer	longest follow-up	Placebo	HR 1.33 (0.13 to 14.13)	0.38
Type 2 diabetes (adults)	Pancreatic cancer	longest follow-up	Placebo	HR 1.20 (0.11 to 13.36)	0.40
Type 2 diabetes (adults)	Any cancer	longest follow-up	Placebo	HR 3.57 (0.52 to 23.60)	0.17
Type 2 diabetes (adults)	Any cancer	longest follow-up	Placebo	HR 3.93 (0.54 to 25.22)	0.16
Type 2 diabetes (adults)	Acute kidney injury	longest follow-up	Placebo	HR 0.49 (0.03 to 6.48)	0.56
Overweight or obesity without diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 5.20 (0.22 to 89.93)	0.23
Overweight or obesity without diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 3.79 (0.17 to 69.51)	0.31
Overweight or obesity without diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.12 (0.00 to 1.40)	0.97
Overweight or obesity without diabetes (adults)	Nausea	longest follow-up	Placebo	HR 0.14 (0.00 to 1.77)	0.95
Overweight or obesity without diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.14 (0.00 to 2.25)	0.92
Overweight or obesity without diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.19 (0.00 to 3.19)	0.89

Trials

PIONEER 12
China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
2019 · 1,441 randomized · 26 weeks
NCT03101930
Cardiovascular Effects of GLP-1 Receptor Activation
2017 · 93 randomized · 14 weeks
SUSTAIN
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial
2017 · 868 randomized · 30 weeks
PIONEER 7
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus
2016 · 504 randomized · 104 weeks
PIONEER 3
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
2016 · 1,864 randomized · 78 weeks
LIGHT-ON
Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease
2014 · 75 randomized · 26 weeks
SUSTAIN™
Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes
2014 · 308 randomized · 30 weeks
NCT02200991
A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus
2014 · 136 randomized · 4 weeks
LIRA-SWITCH™
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
2013 · 407 randomized · 26 weeks
NCT02008682
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)
2013 · 368 randomized · 26 weeks
DURATION-NEO-2
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
2013 · 365 randomized · 28 weeks
SUSTAIN™ 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)
2013 · 1,231 randomized · 56 weeks
GRADE
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
2013 · 5,047 randomized · 365.26 weeks
NCT01296412
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy
2011 · 653 randomized · 26 weeks
S003071
2010 · 99 randomized · 24 weeks
NCT00976937
A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin
2009 · 319 randomized · 24 weeks
NCT00676338
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes
2008 · 820 randomized · 26 weeks
NCT00971659
Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily
2008 · 48 randomized · 4 weeks
NCT00775684
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
2008 · 47 randomized · 26.07 weeks
NCT00700817
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension
2008 · 665 randomized · 26 weeks
NCT00754988
A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.
2008 · 666 randomized · 156 weeks
NCT00637273
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
2008 · 514 randomized · 26 weeks

Sitagliptin

Related

Effects across outcomes

Trials